Silverarc Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Silverarc Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13,765	Closed	-$4.79M	–	87
2023 Q3	$4.79M	Buy	13,765 +590	+4%	+$206K	1.45%	31
2023 Q2	$4.64M	Sell	13,175 -6	-0%	-$2.02K	1.43%	25
2023 Q1	$4.15M	Buy	13,181 +1,797	+16%	+$539K	1.71%	25
2022 Q4	$3.29M	Buy	11,384 +279	+3%	+$85K	0.94%	39
2022 Q3	$3.21M	Buy	11,105 +691	+7%	+$199K	1.09%	30
2022 Q2	$2.94M	Buy	10,414 +2,776	+36%	+$743K	0.9%	32
2022 Q1	$1.99M	Buy	7,638 +2,638	+53%	+$626K	0.82%	30
2021 Q4	$1.1M	Buy	+5,000	New	+$972K	0.45%	59
2021 Q2	–	Sell	-7,500	Closed	-$1.61M	–	115
2021 Q1	$1.61M	Buy	7,500 +2,500	+50%	+$549K	0.88%	42
2020 Q4	$1.18M	Buy	+5,000	New	+$1.15M	0.69%	47

Other funds holding VRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Silverarc Capital Management's VRTX Position: Q4 2023 in Review

Silverarc Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2023, closing a stake of 13,765 shares — an estimated $4.79M sold.

Silverarc Capital Management first reported a position in VRTX in Q4 2020 and held it in 10 quarters. The position peaked at $4.79M in Q3 2023. 1,439 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

Silverarc Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Silverarc Capital Management sold 13,765 Vertex Pharmaceuticals shares in Q4 2023, an estimated $4.79M.
Silverarc Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 10 quarters.
Silverarc Capital Management's Vertex Pharmaceuticals position peaked at $4.79M in Q3 2023.
1,439 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on Silverarc Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.